Market research
AJANTPHARM.NSE Ajanta Pharma Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 422B
- P/E ratio
- 37.24
- Analyst target
- 3808.3845
- Dividend yield
- 0.8%
- Beta
- 0.22
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE031B01049
- Market cap
- 422B
- P/E ratio
- 37.24
- Analyst target
- 3808.3845
- Dividend yield
- 0.8%
- Beta
- 0.22
About
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company engages in the development, manufacture, and marketing of specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, eye drops, dry powder suspension, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, gynaecology, nephrology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
Research context
Ajanta Pharma Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the AJANTPHARM.NSE discussion.
5 years, 6 months ago
Ajanta Pharma Limited is currently in a long term uptrend where the price is trading 23.0% above its 200 day moving average.
From a valuation standpoint, the stock is 12.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 5.4.
Ajanta Pharma Limited's total revenue rose by 15.0% to $7B since the same quarter in the previous year.
Its net income has increased by 64.2% to $2B since the same quarter in the previous year.
Finally, its free cash flow grew by 32.4% to $3B since the same quarter in the previous year.
Based on the above factors, Ajanta Pharma Limited gets an overall score of 4/5.